Core Insights - The stock price of the biopharmaceutical company,药捷安康-B (2617.HK), surged by 124% to a peak of 431.4 HKD, closing at 415 HKD, marking a 115.58% increase, with a market capitalization exceeding 160 billion HKD [1] - Since its IPO on June 23, the stock price has increased over 30 times from the initial price of 13.15 HKD [1] Company Overview - 药捷安康 is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [3] - The company's core product, Tinengotinib, is a unique MTK inhibitor in the registration clinical stage, targeting several recurrent or difficult-to-treat solid tumors [3] Clinical Development - On September 10, 药捷安康 announced that its core product, Tinengotinib, in combination with Fulvestrant, received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial targeting hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer, with the trial set to commence on September 10, 2025 [3]
港股药捷安康今日再涨115.58%报415港元，上市不到3个月飙升超30倍！市值升破1600亿港元
Ge Long Hui·2025-09-15 08:57